Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial

Lancet

Volumn 361, Issue 9375, 2003, Pages 2099-2106

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PLATINUM;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEMATOLOGIC DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEURITIS; NEUROLOGIC DISEASE; OVARY CANCER; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0037862963     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13718-X     Document Type: Article

References (19)

1. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer. 37:2001;S4-66.
2. ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 352:1998;1571-1576.
3. Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br J Cancer. 78:1998;1479-1487.
4. Markman M., Reichman B., Hakes T., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
5. Trimble E.L., Adams J.D., Vena D., et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol. 11:1993;2405-2410·6.
6. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 360:2002;505-515.
7. Rose P.G., Fusco N., Fluellen L., et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol. 16:1998;1494-1497.
8. Dizon D.S., Hensley M.L., Poynor E.A., et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol. 20:2002;1238-1247.
9. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1987;1748-1756.
10. Parmar M.K.B., Machin D. Survival analysis: a practical approach. 1995;John Wiley, Chichester.
11. Fayers PMF, Aaronson NK, Bjordal K, Curran D, Groenvold M, on behalf of the EORTC Quality of Life Study Group. EORTC QLQ-C30 scoring manual, 3rd edn. Brussels: European Organisation for the Research and Treatment of Cancer, 2001: 86.
12. Girling D., Parmar M.K.B., Stenning S., Stephens R., Stewart L. Clinical trials in cancer. 2003;Oxford University Press, Oxford.
13. Cantù M.G., Buda A., Parma G., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol. 20:2002;1232-1237.
14. McGuire W.P., Hoskins W., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
15. Piccart M.J., Bertelsen K., James K., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year result. J Natl Cancer Inst. 92:2000;699-708.
16. Muggia F.M., Braly P.S., Brady M.F., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 18:2000;106-115.
17. Sandercock J., Parmar M.K.B., Torri V., et al. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer. 87:2002;815-824.
18. Gonzalez Martin AA, Calro E, Bover I, et al. Randomised phase II study of carboplatin versus paclitaxel-carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma with assessment of quality of life: a GEICO study (Spanish Group for Investigation on Ovarian Carcinoma). Proc ASCO 2003; 22: (abstr 1812).
19. van Warmerdam L.J., Huizing M.T., Giaccone G., et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol. 24:(suppl 2):1997;97-104.